Kazia Therapeutics Limited has announced the initiation of a Phase 1b clinical trial for its drug paxalisib in patients with advanced breast cancer. The trial, sponsored by Kazia, will explore the effectiveness of paxalisib, a dual PI3K/mTOR inhibitor, when used in combination with either olaparib or pembrolizumab. This multi-center, open-label, randomized study aims to assess the safety, tolerability, and preliminary efficacy of these treatment combinations. The trial will also conduct deep biomarker profiling to aid future development and evaluate early signals of clinical activity. This marks a significant step for Kazia as it extends the application of paxalisib beyond brain cancer to other solid tumors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.